Panel Discussion: The Impact of AI in Precision Oncology

Precision oncology benefits from a wide array of data modalities, including genomics, clinical information, imaging data, pathological findings, and real-world evidence. Integrating and analyzing these diverse datasets enables a holistic understanding of cancer biology, enhances treatment decision-making, supports the development of novel therapies, and ultimately leads to improved outcomes for cancer patients.

Join us for a unique opportunity to revisit a compelling panel discussion featuring healthcare visionaries, originally held at NASDAQ Headquarters on September 26, 2023. Our panelists will delved into the intricate landscape of AI's impact on transforming access to precision therapies, validating research outcomes, refining treatment approaches, and advancing our comprehension of cancer biology.

Register now to be a part of this event.

Agenda

Opportunities of AI integration in healthcare
Regulatory processes and ethical implications
Current uses of AI in clinical practices and research

Featured Presenters

Moderator: Peter Casasanto
Chief BioPharma Officer, SOPHiA GENETICS

Pedram Razavi, MD, PhD
Medical Oncologist, Director of Liquid Biopsy Technologies & Genomics, MSK

Tom Mikkelsen, MD
Medical Director, Precision Medicine Program & Clinical Trials, Henry Ford Health

Ashita Batavia, MD
Head of Hematology & Oncology Data Sciences, R&D, Janssen

Sunil Verma, MD
SVP, Global Head of Oncology, Medical, AstraZeneca

David Rhew, MD
Chief Medical Officer & VP Healthcare, Microsoft

Disclaimer: Captions are automatically generated. All rights reserved. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

Watch Webinar

URL

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Institution(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone(Required)

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

CAPTCHA

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services